Classification and Prognostic Stratification Based on Genomic Features in Myelodysplastic and Myeloproliferative...

Area of Science:

• Hematology
• Genomics
• Oncology

Background:

• Myeloid neoplasms are a heterogeneous group of blood disorders.
• Current classifications may not fully capture the spectrum of these diseases.
• Understanding genomic drivers is crucial for accurate diagnosis and prognosis.

Purpose of the Study:

• To analyze clinical and genomic data of patients with myeloproliferative neoplasm (MPN), myelodysplastic neoplasm (MDS), and overlapping conditions.
• To redefine disease classification based on genomic patterns.
• To correlate genomic groups with clinical outcomes and treatment responses.

Main Methods:

• Collected clinico-genomic data from 1585 patients with MPN, MDS, MDS/MPN, and aplastic anemia (AA).
• Utilized a Dirichlet process (DP) to categorize 53 recurrent genomic abnormalities into 10 distinct groups.
• Correlated genomic groups with specific mutations, survival data, and disease subtypes.

Main Results:

• Identified 10 genomic groups (DP1-DP10) with distinct clinical and prognostic implications.
• Groups DP1 (JAK2 mutations) and DP5 (CALR mutations) showed favorable prognoses in MPN.
• Groups DP2 (TP53/complex karyotype in MDS), DP7 (SETBP1 mutations), and DP9 (NPM1 mutations) indicated adverse prognoses.
• Groups DP10 (SF3B1 mutations) and DP8 (DDX41 mutations/1q derivatives) presented a favorable risk profile.
• Transplantation improved survival in patients within DP2, DP7, and DP9.

Conclusions:

• Genomic classification provides a powerful tool for understanding and managing myeloid neoplasms.
• Personalized treatment strategies can be guided by these genomic subgroups.
• This approach enhances the precision of diagnosis and prognostication in hematologic malignancies.